Newly Public, Arrayit Sets Sights on Molecular Dx to 'Pick Up Where Research Left Off'

President and co-founder Mark Schena said the company aims to "transition" itself "from a life-sciences research-oriented company to a life-sciences health-care company." Developing diagnostic applications on its arrays are part of that effort.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.